ClinicalTrials.gg
Not yet recruitingNCT07857434VLPE-ACLFUpdated Oct 5, 2026

Very Low-volume Plasma Exchange in ACLF

An interventional study of Double Plasma Molecular Adsorption System (DPMAS) and Low-volume plasma exchange in Acute on Chronic Liver Failure (ACLF), sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University — 6 open to participants now, 8 under way, none of them phase 3. Acute-On-Chronic Liver Failure · Third Affiliated Hospital, Sun Yat-Sen University.

Planned enrollment
Largest of 11
840 · median 60
Started
2026
with 1 other
No phase
6 of 13
4 open now
Registered
13th of 13
by date

Among the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 with no phase, and was the 13th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

6 of the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, or all of them as a file.
02

Study summary

This is a prospective, multicenter, open-label, non-inferiority, randomized controlled trial evaluating the efficacy and safety of very low plasma exchange (400 mL plasma + prothrombin complex concentrate) and plasma-free (prothrombin complex concentrate only) artificial liver support systems compared with standard low-volume plasma exchange (1000 mL plasma) in patients with acute-on-chronic liver failure (ACLF). A total of 840 eligible patients (COSSH grade 1-2) will be enrolled from 10 centers across China and randomly assigned in a 1:1:1 ratio to receive three sessions of treatment (every 2-3 days) combined with standard medical therapy. The primary endpoint is 28-day non-liver-transplant mortality, with a non-inferiority margin of 10%. Secondary endpoints include 90-day non-liver-transplant mortality, 90-day bridging to liver transplantation rate, changes in prognostic scores (COSSH-ACLF Ⅱ, MELD, CLIF-C ACLFs) from baseline at 2 weeks, and total plasma volume used during hospitalization. Safety outcomes include adverse events (bleeding, coagulation disorders, thrombosis, hypotension, infections, allergic reactions). The study aims to establish a plasma-sparing treatment strategy that reduces dependence on blood products while maintaining non-inferior efficacy. The trial is funded by the National Science and Technology Major Project of China and approved by the Medical Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Approval No.: 中大附三医伦RG2026-044-01; Approval Date: April 29, 2026). Enrollment is planned from May 2026 to October 2027, with follow-up completed by October 2028. Written informed consent will be obtained from all participants.

Read the detailed description

This prospective, multicenter, open-label, non-inferiority randomized controlled trial aims to evaluate very low plasma (400 mL plasma + PCC) and plasma-free (PCC only) artificial liver support versus standard low-volume plasma exchange (1000 mL) in 840 ACLF patients (COSSH grade 1-2) across 10 Chinese centers. Patients receive three sessions (every 2-3 days) plus standard medical therapy. Primary endpoint: 28-day non-liver-transplant mortality (non-inferiority margin: 10%). Secondary endpoints: 90-day mortality, 90-day bridging to transplant, 2-week prognostic score changes (COSSH-ACLFⅡ/MELD/CLIF-C ACLFs), and total plasma use. Safety: adverse events. Funded by the National Science and Technology Major Project of China. Approved by the Medical Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (RG2026-044-01, April 29, 2026). Enrollment: May 2026-October 2027. Written informed consent required.

03

Conditions studied

  • Acute on Chronic Liver Failure (ACLF)

Keywords

  • acute on chronic liver failure
  • artificial liver support system
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 65 years, inclusive.
  2. Diagnosed with acute-on-chronic liver failure (ACLF) according to the Chinese Guidelines for the Diagnosis and Treatment of Liver Failure (2024), defined as: chronic liver disease (with or without cirrhosis), total (TBil) ≥ 12 mg/dL (≥ 205.2 μmol/L) and (INR) ≥ 1.5.
  3. COSSH-ACLF grade 1 or 2.

Exclusion criteria

Exclusion Criteria:

  1. Patients with malignant tumors.
  2. Pregnant or lactating women.
  3. Patients co-infected with or other immunodeficiency diseases.
  4. Patients with unstable cerebral or cardiovascular infarction, or history of organ transplantation.
  5. End-stage organ failure defined as any of the following: (a) end-stage , end-stage cor pulmonale, brain death or persistent vegetative state, grade IV hepatic encephalopathy; (b) end-stage renal disease or acute renal failure requiring continuous renal replacement therapy (CRRT); (c) mean arterial blood pressure (MAP) persistently below 65 mmHg despite adequate fluid resuscitation, vasoactive agents, and therapy.
  6. count \< 50 × 10⁹/L, severe coagulation disorders, or active bleeding.
  7. History of allergic reactions to extracorporeal circulation, hemoperfusion, or other related materials, or other severe allergies.
  8. Any other conditions that, in the investigator's judgment, make the patient unsuitable for enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
840 participants (estimated)

Study arms

  • Active comparator
    Standard Low-Volume Plasma Exchange (Control Group)

    Participants receive standard medical therapy plus three sessions of dual plasma molecular adsorption system (DPMAS) sequential low-volume plasma exchange (LPE) at intervals of 2-3 days. Each session consists of DPMAS (adsorption volume: 5000 mL, duration: 2-3 hours) followed by plasma exchange with 1000 mL of fresh frozen plasma. Vascular access is established via jugular/ femoral vein catheterization, with heparin or nafamostat used as anticoagulation.

    Other: Double Plasma Molecular Adsorption System (DPMAS) · Other: Low-volume plasma exchange · Other: Standard Medical Therapy

  • Experimental
    Very Low-volume Plasma Exchange with Prothrombin Complex Concentrate

    Participants receive standard medical therapy plus three sessions of dual plasma molecular adsorption system (DPMAS) sequential very low-volume plasma exchange (400 mL) combined with prothrombin complex concentrate (PCC) at intervals of 2-3 days. Each session consists of DPMAS (adsorption volume: 5000 mL, duration: 2-3 hours) followed by plasma exchange with 400 mL of fresh frozen plasma, and immediately thereafter an intravenous infusion of 300-400 IU of prothrombin complex concentrate. Vascular access is established via jugular/ femoral vein catheterization, with heparin or nafamostat used as anticoagulation.

    Other: Double Plasma Molecular Adsorption System (DPMAS) · Drug: Prothrombin Complex Concentrate (PCC) · Other: Standard Medical Therapy · Other: Very low-volume plasma exchange

  • Experimental
    Plasma-Free DPMAS with Prothrombin Complex Concentrate

    Participants receive standard medical therapy plus three sessions of dual plasma molecular adsorption system (DPMAS) combined with prothrombin complex concentrate (PCC) at intervals of 2-3 days, without any plasma exchange. Each session consists of DPMAS (adsorption volume: 5000 mL, duration: 2-3 hours) followed immediately by an intravenous infusion of 300-400 IU of prothrombin complex concentrate. Vascular access is established via jugular/ femoral vein catheterization, with heparin or nafamostat used as anticoagulation.

    Other: Double Plasma Molecular Adsorption System (DPMAS) · Drug: Prothrombin Complex Concentrate (PCC) · Other: Standard Medical Therapy

Interventions

  • OtherDouble Plasma Molecular Adsorption System (DPMAS)

    DPMAS is performed using a hemoperfusion cartridge (HA330-II, Jafron, Zhuhai) and a plasma bilirubin adsorption column (BS330, Jafron, Zhuhai). Each session has an adsorption volume of 5000 mL with a duration of 2-3 hours. The procedure is performed via jugular or femoral vein catheterization, with heparin or nafamostat used for anticoagulation. All three arms receive DPMAS as the core artificial liver support treatment.

  • OtherLow-volume plasma exchange

    Three session of plasma exchange with 1000 mL fresh frozen plasma is performed immediately after DPMAS.

  • DrugProthrombin complex concentrateStudies of Prothrombin complex concentrateProthrombin complex concentrate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prothrombin complex concentrate (300-400 IU) is administered as an intravenous infusion immediately after completion of the artificial liver support system.

  • OtherStandard Medical Therapy

    All participants receive standard medical therapy for acute-on-chronic liver failure per the Chinese Guidelines for the Diagnosis and Treatment of Liver Failure (2024), including antiviral therapy (for HBV/HCV), anti-infective treatment, nutritional support, symptomatic treatment, and prevention/management of complications.

  • OtherVery low-volume plasma exchange

    Three sessions of plasma exchange with 400 mL fresh frozen plasma is performed immediately after DPMAS.

06

What researchers measure

Primary outcomes

  1. 28-Day Non-Liver-Transplant Mortality

    The proportion of participants who die from any cause without liver transplantation within 28 days from enrollment. Survival status is assessed via inpatient monitor of telephone follow-up or outpatient visit.

    Time frame: Day 28 post-enrollment (± 3 days)

Secondary outcomes

  1. 90-Day Non-Liver-Transplant Mortality

    The proportion of participants who die from any cause without liver transplantation within 90 days from enrollment.

    Time frame: 90 days after enrollment

  2. 90-Day Bridging to Liver Transplantation Rate

    The proportion of participants who undergo liver transplantation within 90 days from enrollment.

    Time frame: 90 days after enrollment

  3. Change in Prognostic Scores (COSSH-ACLF Ⅱ, MELD, CLIF-C ACLFs) from Baseline at 2 Weeks

    Changes in three validated acute-on-chronic liver failure (ACLF) prognostic scoring systems at 2 weeks relative to baseline: Chinese Group on the Study of Severe Hepatitis B (COSSH)-ACLF Ⅱ (COSSH-ACLF Ⅱscore = 0.033 × age + 0.396 × ln (serum TBIL) (umol/L) + 1.649 × ln (PT-INR) + 0.576 × ln (serum BUN) (mmol/L) + 0.425 × ln (neutrophil) (10E9/L) + 0.457 × HE score (HE grade 0 = 1, grade 1 and 2 = 2, grade 3 and 4 = 3)), model for end-stage liver disease (MELD, MELD score= 3.78 × ln (serum TBIL) (mg/dL) + 11.20 × ln (PT-INR) + 9.57 × ln (serum creatinine) (mg/dL) + 6.43), and Chronic Liver Failure Consortium (CLIF-C) ACLFs (CLIF-C ACLFs score = 10 × (0.33 × CLIF-OFs + 0.04 × Age + 0.63 × ln(WBC)(10E9/L) - 2) ). Higher score means a worse outcome.

    Time frame: Baseline (Day -2 to 0) to Day 14 post-enrollment (± 3 days)

  4. Total Plasma Volume Used During Hospitalization

    Cumulative total volume of fresh frozen plasma (mL) used from enrollment to discharge, extracted from medical records.

    Time frame: Through study completion, an average of 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ocskay K, Kanjo A, Gede N, Szakacs Z, Par G, Eross B, Stange J, Mitzner S, Hegyi P, Molnar Z. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis. Ann Intensive Care. 2021 Jan 18;11(1):10. doi: 10.1186/s13613-020-00795-0. PubMed 33462764 ↗
  • Saliba F, Banares R, Larsen FS, Wilmer A, Pares A, Mitzner S, Stange J, Fuhrmann V, Gilg S, Hassanein T, Samuel D, Torner J, Jaber S. Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts. Intensive Care Med. 2022 Oct;48(10):1352-1367. doi: 10.1007/s00134-022-06802-1. Epub 2022 Sep 6. PubMed 36066598 ↗
  • Fernandez J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, Reverter E, Martinez J, Saliba F, Jalan R, Welzel T, Pavesi M, Hernandez-Tejero M, Gines P, Arroyo V; European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018 Oct;67(10):1870-1880. doi: 10.1136/gutjnl-2017-314240. Epub 2017 Aug 28. PubMed 28847867 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2028, 25 months later.

Of 32 interventional studies with no phase under Acute-On-Chronic Liver Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 5, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Nov 5, 2028
CompletionEst.
Dec 5, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857434
Responsible party
Liang Peng (Professor, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Nov 5, 2028 (estimated)
Completion
Dec 5, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Liang Peng, M.D.
Contact
pliang@mail.sysu.edu.cn
13533978874

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prothrombin complex concentrate

Start the discussion